Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models

20233 citationsJournal Articlegold Open Access

Authors

EPGN2154 demonstrated a hepato-protective effect independent of body weight loss in preclinical NASH models.

Good health and well-being

Published in: Hepatology Communications

Volume 7, Issue 12

Field-Weighted Citation Impact: 0.66